Subarachnoid Hemorrhage and Inflammation: Bench to Bedside and Back

 

 Buy Article Permissions and Reprints

ABSTRACT

Subarachnoid hemorrhage (SAH) is a devastating and complicated disease. The development of therapeutic interventions has been hampered by a poor understanding of the three components of the disease pathology in SAH: aneurysm rupture, cerebral edema, and vasospasm. The role of inflammation in the pathology of subarachnoid hemorrhage will be reviewed. The events leading up to aneurysm rupture are heralded by degradation of the endothelial cell layer integrity and inflammatory cell infiltration into the wall of the aneurysm. This is associated with release of active agents that can digest the basement membrane and may cause rupture. After rupture, cytokine release by mononuclear leukocytes is associated with early edema. Vasospasm is a complicated process that includes arterial wall thickening and vasoconstriction. Evidence supports the role of inflammation in free radical formation and in perturbations in nitric oxide and endothelin-1 levels that are important mediators of the vasoconstriction in vasospasm. Targeting the inflammatory mediators associated with the three prominent events in SAH is a promising strategy for reducing the mortality and morbidity in these patients. More study is needed to determine which specific effectors in the inflammatory cascade may serve as targets for intervention.

REFERENCES

• 1 Hop J W, Rinkel G J, Algra A, van Gijn J. Changes in functional outcome and quality of life in patients and caregivers after aneurysmal subarachnoid hemorrhage.  J Neurosurg. 2001;  95 957-963
  PubMedGoogle Scholar
• 2 Ingall T J, Whisnant J P, Wiebers D O, O'Fallon W M. Has there been a decline in subarachnoid hemorrhage mortality?.  Stroke. 1989;  20 718-724
  CrossrefPubMedGoogle Scholar
• 3 Shishehbor M H, Brennan M L, Aviles R J et al.. Statins promote potent systemic antioxidant effects through specific inflammatory pathways.  Circulation. 2003;  108 426-431
  CrossrefPubMedGoogle Scholar
• 4 Penn M S, Topol E J. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling.  Circ Res. 2001;  89 1-2
  PubMedGoogle Scholar
• 5 Kovanen P T, Pentikainen M O. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis.  Curr Opin Lipidol. 2003;  14 411-419
  PubMedGoogle Scholar
• 6 Murtagh B M, Anderson H V. Inflammation and atherosclerosis in acute coronary syndromes.  J Invasive Cardiol. 2004;  16 377-384
  PubMedGoogle Scholar
• 7 Smeeth L, Thomas S L, Hall A J, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination.  N Engl J Med. 2004;  351 2611-2618
  CrossrefPubMedGoogle Scholar
• 8 Varsos V G, Liszczak T M, Han D H et al.. Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a “two-hemorrhage” canine model.  J Neurosurg. 1983;  58 11-17
  PubMedGoogle Scholar
• 9 Megyesi J F, Vollrath B, Cook D A, Findlay J M. In vivo animal models of cerebral vasospasm: a review.  Neurosurgery. 2000;  46 448-460
  PubMedGoogle Scholar
• 10 Dumont A S, Dumont R J, Chow M M et al.. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation.  Neurosurgery. 2003;  53 123-133
  PubMedGoogle Scholar
• 11 Krex D, Konig I R, Ziegler A, Schackert H K, Schackert G. Extended single nucleotide polymorphism and haplotype analysis of the elastin gene in Caucasians with intracranial aneurysms provides evidence for racially/ethnically based differences.  Cerebrovasc Dis. 2004;  18 104-110
  CrossrefPubMedGoogle Scholar
• 12 Zhang B, Fugleholm K, Day L B, Ye S, Weller R O, Day I N. Molecular pathogenesis of subarachnoid haemorrhage.  Int J Biochem Cell Biol. 2003;  35(9) 1341-1360
  CrossrefPubMedGoogle Scholar
• 13 Krex D, Ziegler A, Konig I R, Schackert H K, Schackert G. Polymorphisms of the NADPH oxidase P22PHOX gene in a Caucasian population with intracranial aneurysms.  Cerebrovasc Dis. 2003;  16 363-368
  CrossrefPubMedGoogle Scholar
• 14 Takenaka K, Sakai H, Yamakawa H et al.. Polymorphism of the endoglin gene in patients with intracranial saccular aneurysms.  J Neurosurg. 1999;  90 935-938
  PubMedGoogle Scholar
• 15 International Study of Unruptured Intracranial Aneurysms Investigators . Unruptured intracranial aneurysms: risk of rupture and risks of surgical intervention.  N Engl J Med. 1998;  339 1725-1733
  CrossrefPubMedGoogle Scholar
• 16 Juvela S, Porras M, Heiskanen O. Natural history of unruptured intracranial aneurysms: a long-term follow-up study.  J Neurosurg. 1993;  79 174-182
  CrossrefPubMedGoogle Scholar
• 17 Treska V, Kocova J, Boudova L et al.. Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm.  Cytokines Cell Mol Ther. 2002;  7 91-97
  CrossrefPubMedGoogle Scholar
• 18 Frosen J, Piippo A, Paetau A et al.. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases.  Stroke. 2004;  35 2287-2293
  CrossrefPubMedGoogle Scholar
• 19 Kataoka K, Taneda M, Asai T, Kinoshita A, Ito M, Kuroda R. Structural fragility and inflammatory response of ruptured cerebral aneurysms: a comparative study between ruptured and unruptured cerebral aneurysms.  Stroke. 1999;  30 1396-1401
  CrossrefPubMedGoogle Scholar
• 20 Chyatte D, Bruno G, Desai S, Todor D R. Inflammation and intracranial aneurysms.  Neurosurgery. 1999;  45 1137-1146
  CrossrefPubMedGoogle Scholar
• 21 Okawara S H. Warning signs prior to rupture of an intracranial aneurysm.  J Neurosurg. 1973;  38 575-580
  PubMedGoogle Scholar
• 22 Okada Y, Nakanishi I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (“gelatinase”) by human neutrophil elastase and cathepsin G.  FEBS Lett. 1989;  249 353-356
  CrossrefPubMedGoogle Scholar
• 23 Pintucci G, Yu P J, Sharony R et al.. Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2-/- microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2).  J Cell Biochem. 2003;  90 1015-1025
  CrossrefPubMedGoogle Scholar
• 24 Fukuda S, Hashimoto N, Naritomi H et al.. Prevention of rat cerebral aneurysm formation by inhibition of nitric oxide synthase.  Circulation. 2000;  101 2532-2538
  PubMedGoogle Scholar
• 25 Hashimoto N, Handa H, Hazama F. Experimentally induced cerebral aneurysms in rats.  Surg Neurol. 1978;  10 3-8
  PubMedGoogle Scholar
• 26 Abruzzo T, Shengelaia G G, Dawson III R C, Owens D S, Cawley C M, Gravanis M B. Histologic and morphologic comparison of experimental aneurysms with human intracranial aneurysms.  AJNR Am J Neuroradiol. 1998;  19 1309-1314
  PubMedGoogle Scholar
• 27 Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men: results from a representative sample of the general population (MONICA Augsburg Survey 1994/95).  Eur Heart J. 2003;  24 1365-1372
  CrossrefPubMedGoogle Scholar
• 28 de Maat M P, Kluft C. The association between inflammation markers, coronary artery disease and smoking.  Vascul Pharmacol. 2002;  39 137-139
  CrossrefPubMedGoogle Scholar
• 29 Claassen J, Carhuapoma J R, Kreiter K T, Du E Y, Connolly E S, Mayer S A. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome.  Stroke. 2002;  33 1225-1232
  CrossrefPubMedGoogle Scholar
• 30 Fukui S, Nawashiro H, Otani N et al.. Focal brain edema and natriuretic peptides in patients with subarachnoid hemorrhage.  Acta Neurochir Suppl. 2003;  86 489-491
  PubMedGoogle Scholar
• 31 Laszlo F A, Varga C, Doczi T. Cerebral oedema after subarachnoid haemorrhage: pathogenetic significance of vasopressin.  Acta Neurochir (Wien). 1995;  133 122-133
  CrossrefPubMedGoogle Scholar
• 32 Laszlo F A, Varga C, Nakamura S. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.  Eur J Pharmacol. 1999;  364 115-122
  CrossrefPubMedGoogle Scholar
• 33 Aihara Y, Kasuya H, Onda H, Hori T, Takeda J. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage.  Stroke. 2001;  32 212-217
  PubMedGoogle Scholar
• 34 Kusaka G, Ishikawa M, Nanda A, Granger D N, Zhang J H. Signaling pathways for early brain injury after subarachnoid hemorrhage.  J Cereb Blood Flow Metab. 2004;  24 916-925
  PubMedGoogle Scholar
• 35 Croll S D, Ransohoff R M, Cai N et al.. VEGF-mediated inflammation precedes angiogenesis in adult brain.  Exp Neurol. 2004;  187 388-402
  CrossrefPubMedGoogle Scholar
• 36 Ishida S, Usui T, Yamashiro K et al.. VEGF164 is proinflammatory in the diabetic retina.  Invest Ophthalmol Vis Sci. 2003;  44 2155-2162
  CrossrefPubMedGoogle Scholar
• 37 Polin R S, Bavbek M, Shaffrey M E et al.. Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage.  J Neurosurg. 1998;  89 559-567
  PubMedGoogle Scholar
• 38 Mayberg M R, Okada T, Bark D H. Morphologic changes in cerebral arteries after subarachnoid hemorrhage.  Neurosurg Clin N Am. 1990;  1 417-432
  PubMedGoogle Scholar
• 39 Kistler J P, Crowell R M, Davis K R et al.. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study.  Neurology. 1983;  33 424-436
  CrossrefPubMedGoogle Scholar
• 40 Rinkel G J, Wijdicks E F, Vermeulen M, Hasan D, Brouwers P J, van Gijn J. The clinical course of perimesencephalic nonaneurysmal subarachnoid hemorrhage.  Ann Neurol. 1991;  29 463-468
  CrossrefPubMedGoogle Scholar
• 41 Pluta R M, Thompson B G, Afshar J K, Boock R J, Iuliano B, Oldfield E H. Nitric oxide and vasospasm.  Acta Neurochir Suppl. 2001;  77 67-72
  PubMedGoogle Scholar
• 42 Ng W H, Moochhala S, Yeo T T, Ong P L, Ng P Y. Nitric oxide and subarachnoid hemorrhage: elevated level in cerebrospinal fluid and their implications.  Neurosurgery. 2001;  49 622-626
  PubMedGoogle Scholar
• 43 Zuccarello M. Endothelin: the “prime suspect” in cerebral vasospasm.  Acta Neurochir Suppl. 2001;  77 61-65
  PubMedGoogle Scholar
• 44 Allen G S. Role of calcium antagonists in cerebral arterial spasm.  Am J Cardiol. 1985;  55 149B-153B
  CrossrefPubMedGoogle Scholar
• 45 Kivisakk P, Mahad D J, Callahan M K et al.. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin.  Proc Natl Acad Sci USA. 2003;  100 8389-8394
  CrossrefPubMedGoogle Scholar
• 46 Spallone A, Acqui M, Pastore F S, Guidetti B. Relationship between leukocytosis and ischemic complications following aneurysmal subarachnoid hemorrhage.  Surg Neurol. 1987;  27 253-258
  PubMedGoogle Scholar
• 47 Hallenbeck J M, Dutka A J, Tanishima T et al.. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period.  Stroke. 1986;  17 246-253
  PubMedGoogle Scholar
• 48 Handa Y, Kabuto M, Kobayashi H, Kawano H, Takeuchi H, Hayashi M. The correlation between immunological reaction in the arterial wall and the time course of the development of cerebral vasospasm in a primate model.  Neurosurgery. 1991;  28 542-549
  PubMedGoogle Scholar
• 49 Peterson J W, Kwun B D, Hackett J D, Zervas N T. The role of inflammation in experimental cerebral vasospasm.  J Neurosurg. 1990;  72 767-774
  PubMedGoogle Scholar
• 50 Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen-host interaction.  Vaccine. 2003;  21(suppl 2) S12-S23
  CrossrefPubMedGoogle Scholar
• 51 Aihara Y, Kasuya H, Onda H, Hori T, Takeda J. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage.  Stroke. 2001;  32 212-217
  PubMedGoogle Scholar
• 52 Gaetani P, Tartara F, Pignatti P et al.. Cisternal CSF levels of cytokines after subarachnoid hemorrhage.  Neurol Res. 1998;  20 337-342
  PubMedGoogle Scholar
• 53 Kikuchi T, Okuda Y, Kaito N, Abe T. Cytokine production in cerebrospinal fluid after subarachnoid haemorrhage.  Neurol Res. 1995;  17 106-108
  PubMedGoogle Scholar
• 54 Buffon A, Biasucci L M, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina.  N Engl J Med. 2002;  347 5-12
  CrossrefPubMedGoogle Scholar
• 55 Bhatt D L, Topol E J. Need to test the arterial inflammation hypothesis.  Circulation. 2002;  106 136-140
  CrossrefPubMedGoogle Scholar
• 56 Scheld W M, Koedel U, Nathan B, Pfister H W. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury.  J Infect Dis. 2002;  186(suppl 2) S225-S233
  CrossrefPubMedGoogle Scholar
• 57 Hazen S L, Hsu F F, Mueller D M, Crowley J R, Heinecke J W. Human neutrophils employ chlorine gas as an oxidant during phagocytosis.  J Clin Invest. 1996;  98 1283-1289
  PubMedGoogle Scholar
• 58 Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage.  Lancet. 1989;  2 1402
  PubMedGoogle Scholar
• 59 Zubkov A Y, Rollins K S, Parent A D, Zhang J, Bryan Jr R M. Mechanism of endothelin-1-induced contraction in rabbit basilar artery.  Stroke. 2000;  31 526-533
  PubMedGoogle Scholar
• 60 Fassbender K, Hodapp B, Rossol S et al.. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes.  Stroke. 2000;  31 2971-2975
  PubMedGoogle Scholar
• 61 Thomas J E, Nemirovsky A, Zelman V, Giannotta S L. Rapid reversal of endothelin-1-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors.  Neurosurgery. 1997;  40 1245-1249
  PubMedGoogle Scholar
• 62 Sehba F A, Schwartz A Y, Chereshnev I, Bederson J B. Acute decrease in cerebral nitric oxide levels after subarachnoid hemorrhage.  J Cereb Blood Flow Metab. 2000;  20 604-611
  PubMedGoogle Scholar
• 63 Goksel H M, Karadag O, Turaclar U, Tas F, Oztoprak I. Nitric oxide synthase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental cerebral vasospasm model.  Acta Neurochir (Wien). 2001;  143 383-390 discussion 390-381
  CrossrefPubMedGoogle Scholar
• 64 Lin C L, Calisaneller T, Ukita N, Dumont A S, Kassell N F, Lee K S. A murine model of subarachnoid hemorrhage-induced cerebral vasospasm.  J Neurosci Methods. 2003;  123 89-97
  CrossrefPubMedGoogle Scholar
• 65 Goodman J C, Feng Y Q, Valadka A B, Bryan R J, Robertson C S. Measurement of the nitric oxide metabolites nitrate and nitrite in the human brain by microdialysis.  Acta Neurochir Suppl. 2002;  81 343-345
  PubMedGoogle Scholar
• 66 Ohta H, Ito Z, Yasui N, Suzuki A. Extensive evacuation of subarachnoid clot for prevention of vasospasm: effective or not?.  Acta Neurochir (Wien). 1982;  63 111-116
  CrossrefPubMedGoogle Scholar
• 67 Thomas J E, McGinnis G. Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting.  Stroke. 2002;  33 486-492
  CrossrefPubMedGoogle Scholar
• 68 Chen D, Nishizawa S, Yokota N, Ohta S, Yokoyama T, Namba H. High-dose methylprednisolone prevents vasospasm after subarachnoid hemorrhage through inhibition of protein kinase C activation.  Neurol Res. 2002;  24 215-222
  CrossrefPubMedGoogle Scholar
• 69 Shibata S, Suzuki S, Ohkuma H, Kimura M, Fujita S. Effects of intracisternal methylprednisolone on lipid peroxidation in experimental subarachnoid haemorrhage.  Acta Neurochir (Wien). 1999;  141 529-532
  CrossrefPubMedGoogle Scholar
• 70 Haley Jr E C, Kassell N F, Apperson-Hansen C, Maile M H, Alves W M. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.  J Neurosurg. 1997;  86 467-474
  PubMedGoogle Scholar
• 71 Manno E M, Gress D R, Ogilvy C S, Stone C M, Zervas N T. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot study.  Neurosurgery. 1997;  40 289-293
  CrossrefPubMedGoogle Scholar
• 72 El Bekay R, Alvarez M, Monteseirin J et al.. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB.  Blood. 2003;  102 662-671
  CrossrefPubMedGoogle Scholar

J. Javier ProvencioM.D. 

Assistant Professor, Lerner Cleveland Clinic College of Medicine of CWRU, Cleveland Clinic Foundation Neurology/S90, Cleveland, OH 44195